 |
| Credit CDC |
#14,139
Three years ago (June 2016) the CDC issued a Clinical Alert to U.S. Healthcare facilities over the Global Emergence of Invasive Infections Caused by the Multidrug-Resistant Yeast Candida auris, and since then we've been watching its spread - primarily in health care facilities - both in the United States and around the world.
Candida Auris: CDC June Update & Other Resources
Notes from the Field: Surveillance for Candida auris — Colombia, September 2016–May 2017)
ECDC: C. Auris Rapid Risk Assessment For Healthcare Settings - Europe
mSphere: Comparative Pathogenicity of UK Isolates of the Emerging Candida auris
 |
| C. Auris Sureveilance Map - June 2019 |
C. auris is an emerging fungal pathogen that was first isolated in Japan in 2009. It was initially found in the discharge from a patient's external ear (hence the name `auris'). Retrospective analysis has traced this fungal infection back over 20 years.
Complicating matters:
- C. auris infections have a high fatality rate
- The strain appears to be resistant to multiple classes of anti-fungals
- This strain is unusually persistent on fomites in healthcare environments.
- And it can be difficult for labs to differentiate it from other Candida strains
Later today the CDC will hold a COCA (Clinician Outreach Communication Activity) call to update practitioners on the current status of this threat, review its epidemiology, and provide guidance on the treatment, identification, and control of C. auris.
Multidrug-resistant Candida auris: Update on Current U.S. Epidemiology, Clinical Profile, Management, and Control Strategies= Free Continuing Education
Date: Thursday, June 20, 2019
Time: 2:00pm-3:00pm (Eastern Time)
Instructions for Obtaining Continuing Education (CE)
To receive continuing education (CE) for WC2922-062019—(Webcast) Clinician Outreach and Communication Activity (COCA) Calls/Webinars “Multi-drug Resistant Candida auris: Update on Current U.S. Epidemiology, Clinical Profile, Management, and Control Strategies” Thursday, June 20, 2019, please visit TCEO and follow these 9 Simple Steps by July 22, 2019.
To receive continuing education (CE) for WD2922-062019—(Web on demand) Clinician Outreach and Communication Activity (COCA) Calls/Webinars “Multi-drug Resistant Candida auris: Update on Current U.S. Epidemiology, Clinical Profile, Management, and Control Strategies” Thursday, June 20, 2019, please visit TCEO and follow these 9 Simple Steps by July 23, 2021.
A few minutes before the webinar begins on Thursday, June 20, 2019, please click the link below to join the webinar:
https://zoom.us/j/628944137external icon
Or iPhone one-tap :
US: +16468769923,,628944137# or +16699006833,,628944137#
Or Telephone:
Dial(for higher quality, dial a number based on your current location):
US: +1 646 876 9923 or +1 669 900 6833
Webinar ID: 628 944 137
International numbers available: https://zoom.us/u/anixAVglVexternal icon
Overview
Candida auris (C. auris) is an emerging fungus that presents a serious global health threat. CDC is concerned about C. auris for 3 main reasons:
Most C. auris cases in the United States have been detected in the New York City area, New Jersey, and the Chicago area. Clusters of cases have also recently been described in Florida, Texas, and California. C. auris cases in the United States are originally a result of inadvertent introduction into the United States from a patient who had received healthcare in a country where C. auris has been reported. Most cases now are a result of local spread after such an introduction.
- It is often multidrug-resistant, meaning multiple antifungal drugs are less or not at all effective in treating C. auris.
- It is difficult to identify with standard laboratory methods, and it can be misidentified in labs without specific technology. Misidentification may lead to inappropriate management.
- It has caused outbreaks in healthcare settings. It is important to quickly identify C. auris in a hospitalized patient so that healthcare facilities can take special precautions to stop its spread.
During this COCA Call, CDC presenters will
(Continue . . . )
- Provide an update on the current status of auris
- Explain why it is a public health threat
- Review current U.S. epidemiology and resistance patterns to antifungal drugs
- Discuss clinical considerations when treating patients for auris
- Lay out steps for identifying and controlling C. auris.
If you are unable to watch the live presentation, COCA calls are archived within a few days and remain available for viewing, with presentations going back to 2016.
This is the 7th COCA Call of 2019, with links to the previous six listed below:
